Avoid common mistakes on your manuscript.
To the Editor, we would like to share ideas on the publication “Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab [1].” Even while the serological response to the SARS-CoV-2 vaccination is substantially compromised in patients treated with B-cell-targeting therapy, Bacova et al. determined that the majority of these patients generate adequate cell-mediated immunity. As a result, immunization of these patients could be beneficial in terms of preventing SARS-CoV-2 infection [1]. We agree that the mRNA vaccination has the potential to elicit an immunological response. The potential confounding factor due to asymptomatic COVID-19 is a major worry in the current report. Asymptomatic COVID-19 is not uncommon, and asymptomatic COVID-19 can occur before or after vaccination [2]. The asymptomatic COVID-19 can make it difficult to evaluate the immunological markers being investigated.
References
Bacova B, Kohutova Z, Zubata I, Gaherova L, Kucera P, Heizer T, Mikesova M, Karel T, Novak J. Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab. Clin Exp Med. 2022. https://doi.org/10.1007/s10238-022-00809-0.
Joob B, Wiwanitkit V. Letter to the Editor: Coronavirus Disease 2019 (COVID-19), infectivity, and the incubation period. J Prev Med Public Health. 2020;53(2):7.
Funding
None.
Author information
Authors and Affiliations
Contributions
mungmunpuntipantip r 50 % ideas, writing, aanlyzing, approval for submission wiwanitkit v 50 % ideas, supervising, approval for submission
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mungmunpuntipantip, R., Wiwanitkit, V. Comment on “immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab”. Clin Exp Med 23, 955 (2023). https://doi.org/10.1007/s10238-022-00883-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10238-022-00883-4